Drug intelligence / Profile preview

mupirocin + hexachlorophene

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Intranasal, Topical

Overview

A combination antimicrobial regimen consisting of mupirocin (a topical antibiotic) and hexachlorophene (a bacteriostatic skin cleanser). This combination is primarily used for decolonization of methicillin-resistant Staphylococcus aureus (MRSA) and prevention of recurrent skin infections. Mupirocin works by inhibiting bacterial protein synthesis through blocking isoleucyl-tRNA synthetase, while hexachlorophene acts as a bacteriostatic agent against gram-positive bacteria.

Targets

IleRS (Isoleucyl-tRNA synthetase)

Beyond the preview

Go deeper on mupirocin + hexachlorophene.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mupirocin + hexachlorophene.

Explore the full profile